Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma

Cancer

Volumn 106, Issue 4, 2006, Pages 900-906

  Pawlik, Timothy M ^a   Ross, Merrick I ^a   Prieto, Victor G ^a   Ballo, Matthew T ^a   Johnson, Marcella M ^a   Mansfield, Paul F ^a   Lee, Jeffrey E ^a   Cormier, Janice N ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Desmoplastic melanoma; Sentinel lymph node biopsy

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; THICKNESS; TUMOR VOLUME;

FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE PLANNING; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SKIN ULCER;

EID: 32544450833     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21635     Document Type: Article

References (42)

1. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914-936.
2. Fearns C, Dowdle EB. The desmoplastic response: induction of collagen synthesis by melanoma cells in vitro. Int J Cancer. 1992;50:621-627.
3. Reed RJ, Leonard DD. Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol. 1979;3:301-311.
4. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998;83:1128-1135.
5. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol. 1989;13:358-373.
6. Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg. 2001;182:590-595.
7. Gyorki DE, Busam K, Panageas K, Brady MS, Coit DG. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol. 2003;10:403-407.
8. Thelmo MC, Sagebiel RW, Treseler PA, et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol. 2001;44:451-455.
9. Payne WG, Kearney R, Wells K, et al. Desmoplastic melanoma. Am Surg. 2001;67:1004-1006.
10. Egbert B, Kempson R, Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer. 1988;62:2033-2041.
11. Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma: patterns of recurrence. World J Surg. 1992;16:186-190.
12. Beenken S, Byers R, Smith JL, Goepfert H, Shallenberger R. Desmoplastic melanoma. Histologic correlation with behavior and treatment. Arch Otolaryngol Head Neck Surg. 1989;115:374-379.
13. Devaraj VS, Moss AL, Briggs JC. Desmoplastic melanoma: a clinico-pathological review. Br J Plast Surg. 1992;45:595-598.
14. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478-494.
15. Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Cancer. 2004;100:598-604.
16. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol. 2004;11:362-374.
17. Ross MI, Reinigen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol. 1993;9:219-223.
18. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
19. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
20. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
21. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654-658; discussion 659-660.
22. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 2004;28:1518-1525.
23. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207-213.
24. Scolyer RA, Thompson JF. Desmoplastic melanoma: a heterogeneous entity in which subclassification as "pure" or "mixed" may have important prognostic significance. Ann Surg Oncol. 2005;12:197-199.
25. Rousseau DL Jr., Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-574.
26. Prieto VG, Clark SH. Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol. 2002;6:257-264.
27. Lemeshow S, Hosmer D. Applied logistic regression. New York: John Wiley & Sons, 2000.
28. Bruijn JA, Mihm MC Jr., Barnhill RL. Desmoplastic melanoma. Histopathology. 1992;20:197-205.
29. Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995;32:717-725.
30. Whitaker DC, Argenyi Z, Smith AC. Desmoplastic malignant melanoma: rare and difficult to diagnose. J Am Acad Dermatol. 1992;26:704-709.
31. Kaneishi NK, Cockerell CJ. Histologic differentiation of desmoplastic melanoma from cicatrices. Am J Dermatopathol. 1998;20:128-134.
32. Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60:1800-1808.
33. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72-77.
34. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Huntingt). 2004;18:99-107; discussion 107-110, 113-114.
35. Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003;25:423-428.
36. Anderson TD, Weber RS, Guerry D, et al. Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy. Head Neck. 2002;24:1068-1071.
37. Anstey A, McKee P, Jones EW. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br J Dermatol 1993;129:359-371.
38. Walsh NM, Roberts JT, Orr W, Simon GT. Desmoplastic malignant melanoma. A clinicopathologic study of 14 cases. Arch Pathol Lab Med. 1988;112:922-927.
39. Baer SC, Schultz D, Synnestvedt M, Elder DE. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer. 1995;76:2242-2247.
40. Gershenwald JE, Bar-Eli M. Gene expression profiling of human cutaneous melanoma: are we there yet? Cancer Biol Ther. 2004;3:121-123.
41. Busam K, Zhao H, Coit DG, et al. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J Invest Dermatol. 2005;124:412-418.
42. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer. 2005;103:788-792.